Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
| Autor: | Dong Wang, Xueqin Yang, Hongyi Wang, Nan Dai, Laura Baugh, Chuan Chen, Shiheng Zhang, David M. Wilson, Yi Qing, Zhaoyang Zhong, Wei Guan, Gianluca Tell, Jinlu Shan, Mengxia Li, Le He, Feng Jin, Yuxin Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Male Lung Neoplasms medicine.medical_treatment Gene Expression NSCLC 0302 clinical medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols DNA-(Apurinic or Apyrimidinic Site) Lyase Aged 80 and over Predictive marker medicine.diagnostic_test Middle Aged Prognosis Treatment Outcome 030220 oncology & carcinogenesis Biomarker (medicine) Immunohistochemistry Female Research Paper Adult medicine.medical_specialty Enzyme-Linked Immunosorbent Assay 03 medical and health sciences Internal medicine Biopsy medicine Biomarkers Tumor Humans Chemotherapy Lung cancer Aged Neoplasm Staging Platinum Proportional Hazards Models Proportional hazards model business.industry Cancer Biomarker medicine.disease Surgery APE1 030104 developmental biology ROC Curve business |
| Zdroj: | Oncotarget |
| Popis: | // Shiheng Zhang 1, * , Le He 1, * , Nan Dai 1 , Wei Guan 1 , Jinlu Shan 1 , Xueqin Yang 1 , Zhaoyang Zhong 1 , Yi Qing 1 , Feng Jin 1 , Chuan Chen 1 , Yuxin Yang 1 , Hongyi Wang 4 , Laura Baugh 4 , Gianluca Tell 2 , David M. Wilson III 3 , Mengxia Li 1 , Dong Wang 1 1 Cancer Center of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, China 2 Laboratory of Molecular Biology and DNA repair, Department of Medical and Biological Sciences, University of Udine, Udine 33100, Italy 3 Laboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA 4 Department of Pathology, Baylor University Medical Center, Dallas, TX 75246, USA 5 Tianjin HUABOTE Biotechnological Inc., Tianjin 300350, China * These authors contributed equally to this work Correspondence to: Mengxia Li, email: mengxia.li@outlook.com Dong Wang, email: dongwang64@hotmail.com Keywords: APE1, NSCLC, chemotherapy, biomarker Received: March 17, 2016 Accepted: October 14, 2016 Published: November 02, 2016 ABSTRACT Purpose: To define the role of the DNA repair protein apurinic/apyrimidinic endonuclease 1 (APE1) in predicting the prognosis and chemotherapeutic response of non-small cell lung cancer patients receiving platinum-containing chemotherapy. Results: Our investigations found that serum APE1 level was significantly elevated in 229 of 412 NSCLC patients and correlated with its level in tissue ( r 2 = 0.639, p < 0.001). The elevated APE1 level in both tissue and serum of patients prior to chemotherapy was associated with worse progression-free survival (HR: 2.165, p < 0.001, HR: 1.421, p = 0.012), but not with overall survival. After 6 cycles of chemotherapy, a low APE1 serum level was associated with better overall survival (HR: 0.497, p = 0.010). Experimental Design: We measured APE1 protein levels in biopsy tissue from 172 NSCLC patients and sera of 412 NSCLC patients receiving platinum-based chemotherapy by immunohistochemistry and a newly established sensitive and specific enzyme-linked immunosorbent assay, respectively. APE1 levels in sera of 523 healthy donors were also determined as control. Conclusions: Our studies indicate that APE1 is a biomarker for predicting prognosis and therapeutic efficacy in NSCLC. The chemotherapy-naive serum APE1 level, which correlated with its tissue level inversely associated with progression-free survival of platinum-containing doublet chemotherapy, whereas post-treatment serum APE1 level was inversely associated with overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|